Caplin Point gains USFDA nod for Calcium Gluconate Injection targeting $191M US market

Market snapshot: Caplin Point Laboratories Ltd has announced that its subsidiary, Caplin Steriles Limited, has received final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Calcium Gluconate Injection USP. This approval covers the 1,000 mg/10 mL and 5,000 mg/50 mL vials, strengthening the company's presence in the US sterile injectables space.

Data Snapshot

• Market Size: ~$191 Million (IQVIA annual sales ending Dec 2025)
• Dosage Strengths: 1,000 mg/10 mL and 5,000 mg/50 mL
• Approval Status: Final USFDA ANDA Approval
• Subsidiary: Caplin Steriles Ltd

What's Changed

• Portfolio Expansion: Transitioning from a small-cap generic player to a specialized sterile injectable provider in the US.
• Revenue Potential: The approval unlocks access to a nearly $200 million addressable market for a critical care product.
• Strategic Momentum: This marks a consistent run of ANDA approvals for the Caplin Steriles facility over the last 24 months.

Key Takeaways

• Caplin Steriles continues to demonstrate high regulatory compliance standards with the USFDA.
• Calcium Gluconate is a staple injectable in hospital settings, ensuring steady institutional demand.
• The approval builds on a pipeline of over 20 ANDAs currently under development or review for the US market.

SAHI Perspective

Caplin Point's strategy of focusing on niche, high-entry-barrier sterile injectables via its subsidiary is yielding high-margin regulatory wins. While the $191M market is competitive, Caplin’s lean cost structure typically allows for aggressive market share gains in the generic space.

Market Implications

The approval is expected to provide a medium-term boost to consolidated revenues and EBITDA margins. It signals a positive outlook for the company's US business, which has been the primary engine for its recent valuation rerating.

Trading Signals

Market Bias: Bullish

Consistent ANDA approvals and a target market of $191M for a single product indicate strong revenue visibility and specialized growth in the US pharma segment.

Overweight: Pharmaceuticals, Healthcare - Sterile Injectables

Trigger Factors:

• Commercial launch timelines in the US
• USFDA inspection outcomes of the CP-4 facility
• Quarterly US revenue growth trajectory

Time Horizon: Medium-term (3-12 months)

Industry Context

The US generic injectable market is currently facing supply chain fragilities, creating opportunities for reliable manufacturers like Caplin Steriles to fill supply gaps in essential medicines like Calcium Gluconate.

Key Risks to Watch

• Pricing pressure from larger generic competitors in the US market.
• Potential supply chain disruptions affecting raw material sourcing.
• Regulatory risks associated with ongoing compliance at manufacturing sites.

Recent Developments

In February 2026, Caplin Point reported a 21% increase in consolidated net profit for Q3 FY26, driven by strong growth in Latin American and US markets. The company has also recently announced plans to expand its oncology injectable capacity.

Closing Insight

Caplin Point remains a high-growth pharmaceutical entity leveraging regulatory approvals to scale its footprint in regulated markets while maintaining its dominance in emerging geographies.

FAQs

What is the market size for Calcium Gluconate Injection in the US?

According to IQVIA data, the annual sales for Calcium Gluconate Injection USP in the US were approximately $191 million for the 12-month period ending December 2025.

How does this approval impact Caplin Point's financial outlook?

The approval allows for immediate commercialization in the US, likely contributing to double-digit revenue growth in the sterile injectables segment over the next 4-6 quarters.

Does this approval affect retail medicine availability in India?

No, this is a USFDA approval specifically for the United States market and relates to institutional/hospital-use injectables rather than retail pharmacy products in India.

High Performance Trading with SAHI.